PURPOSE: To determine whether subjects with human immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) show altered concentrations of brain glutamate (GLU), and whether lower GLU levels correlate with cognitive deficits. MATERIALS AND METHODS: GLU concentrations were measured in the basal ganglia, frontal gray and white matter, and parietal gray matter of 45 HIV-positive and 46 age-and-education-matched HIV-negative subjects using echo-time averaged proton magnetic resonance spectroscopy ((1)H MRS). RESULTS: Compared to controls, HIV subjects with cognitive deficits had lower GLU in the parietal gray matter, while those without cognitive deficits tended to show higher basal ganglia GLU. Lower parietal and frontal gray matter GLU were associated with a greater number of nucleoside reverse transcriptase inhibitors, and were predictive of poorer cognitive performance. Correlations between GLU and cognitive performance, but not the other findings, remained significant after correction for multiple comparisons. CONCLUSION: Parietal gray matter GLU is lower in HIV subjects with cognitive deficits. This reduction might result from reduced astrocytic reuptake of GLU, secondary excitotoxicity, and mitochondrial toxicity from antiretroviral treatments. The glutamatergic system may play an important role in the pathophysiology of HAND, and brain GLU on (1)H MRS may provide an early surrogate marker for monitoring disease severity and treatment effects.
PURPOSE: To determine whether subjects with humanimmunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) show altered concentrations of brain glutamate (GLU), and whether lower GLU levels correlate with cognitive deficits. MATERIALS AND METHODS:GLU concentrations were measured in the basal ganglia, frontal gray and white matter, and parietal gray matter of 45 HIV-positive and 46 age-and-education-matched HIV-negative subjects using echo-time averaged proton magnetic resonance spectroscopy ((1)H MRS). RESULTS: Compared to controls, HIV subjects with cognitive deficits had lower GLU in the parietal gray matter, while those without cognitive deficits tended to show higher basal ganglia GLU. Lower parietal and frontal gray matter GLU were associated with a greater number of nucleoside reverse transcriptase inhibitors, and were predictive of poorer cognitive performance. Correlations between GLU and cognitive performance, but not the other findings, remained significant after correction for multiple comparisons. CONCLUSION: Parietal gray matter GLU is lower in HIV subjects with cognitive deficits. This reduction might result from reduced astrocytic reuptake of GLU, secondary excitotoxicity, and mitochondrial toxicity from antiretroviral treatments. The glutamatergic system may play an important role in the pathophysiology of HAND, and brain GLU on (1)H MRS may provide an early surrogate marker for monitoring disease severity and treatment effects.
Authors: Mark W Woolrich; Saad Jbabdi; Brian Patenaude; Michael Chappell; Salima Makni; Timothy Behrens; Christian Beckmann; Mark Jenkinson; Stephen M Smith Journal: Neuroimage Date: 2008-11-13 Impact factor: 6.556
Authors: C D English; M J Kaufman; J L Worth; S M Babb; C E Drebing; B A Navia; P F Renshaw Journal: Biol Psychiatry Date: 1997-02-15 Impact factor: 13.382
Authors: Zhuying Wang; Gusta Trillo-Pazos; Seon-Young Kim; Mario Canki; Susan Morgello; Leroy R Sharer; Harris A Gelbard; Zao-Zhong Su; Dong-Chul Kang; Andrew I Brooks; Paul B Fisher; David J Volsky Journal: J Neurovirol Date: 2004 Impact factor: 2.643
Authors: Linda Chang; Caroline Jiang; Eric Cunningham; Steven Buchthal; Vanessa Douet; Marilou Andres; Thomas Ernst Journal: Neurology Date: 2014-05-21 Impact factor: 9.910
Authors: R Nagarajan; M K Sarma; M A Thomas; L Chang; U Natha; M Wright; J Hayes; K Nielsen-Saines; D E Michalik; J Deville; J A Church; K Mason; T Critton-Mastandrea; S Nazarian; J Jing; M A Keller Journal: J Neuroimmune Pharmacol Date: 2012-10-13 Impact factor: 4.147